Mavrilimumab

Mavrilimumab Chemische Eigenschaften,Einsatz,Produktion Methoden

Verwenden

Mavrilimumab (CAM-3001) is an investigational human IgG4 monoclonal antibody (MAb) targeting GM-CSF receptor alpha which is currently being developed for the treatment of RA. GM-CSF plays a central role in the pathogenesis of rheumatoid arthritis (RA) through the activation, differentiation, and survival of macrophages and neutrophils.

Mavrilimumab Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

Mavrilimumab Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
Aladdin Scientific		tp@aladdinsci.com	United States	57505	58
Shanghai YuanYe Biotechnology Co., Ltd.	021-61312847; 18021002903	3008007409@qq.com	China	71826	60
ShangHai Biochempartner Co.,Ltd	177-54423994 17754423994	2853530910@QQ.com	China	8000	62
Guangzhou Hongyuan Chemical Co.,Ltd	15817493340	981810490@qq.com	China	1566	58
Wuhan Chemstan Biotechnology Co., Ltd.	027-65317797 15926423062	422450190@qq.com	China	10308	58
TargetMol Chemicals Inc.	4008200310	marketing@tsbiochem.com	China	24961	58
Biolab Reagents	027-65279366 18108604356	products@biolabreagent.com	China	9868	58
Wuhan Jingkangen Biomedical Technology Co., Ltd	13720134139 086-15871494362 13720134139	orders@jknbiochem.com	China	6762	58
Shanghai Yifei Biotechnology Co. , Ltd.	021-65675885 18964387627	customer_service@efebio.com	China	11973	58
Shanghai Aladdin Biochemical Technology Co.,Ltd.	400-6206333 13167063860	anhua.mao@aladdin-e.com	China	48457	58

---

• Mavrilimumab
• Research Grade Mavrilimumab(DHD11501)
• Mavrilimumab (anti-CD116)
• CAM 3001
• Research Grade Mavrilimumab
• 1085337-57-0